53 related articles for article (PubMed ID: 35279890)
1. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
Reich K; Iversen L; Puig L; Lambert J; Mrowietz U; Kaplan Saday K; Warren RB
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1275-1283. PubMed ID: 35279890
[TBL] [Abstract][Full Text] [Related]
2. Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Farahnik B; Beroukhim K; Abrouk M; Nakamura M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
Dermatol Ther (Heidelb); 2016 Jun; 6(2):111-24. PubMed ID: 27221323
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Rigopoulos D; Tampouratzi E; Angelakopoulos C; Apalla Z; Barkis I; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Chasapi V; Sfaelos K; Ioannides D;
J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):1121-1130. PubMed ID: 38308561
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest.
Schaeffer L; Ben-Anaya N; Sorbe C; Rustenbach SJ; Mrowietz U; Augustin M
J Dermatolog Treat; 2024 Dec; 35(1):2340107. PubMed ID: 38636941
[TBL] [Abstract][Full Text] [Related]
5. Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.
Gkalpakiotis S; Kojanová M; Fialová J; Cetkovská P; Vašků V; Vantuchová Y; Machovcová A; Gkalpakioti P; Hrdá P; Arenberger P
Dermatol Ther (Heidelb); 2024 Jan; 14(1):115-130. PubMed ID: 38032433
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA).
Reich K; Bianchi L; Khemis A; Maul JT; Tsianakas A; Schempp CM; Petersen K; Noergaard MM; Puig L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):453-468. PubMed ID: 38300408
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
Sahuquillo-Torralba A; Hospital-Gil M; Vilarrasa-Rull E; Llamas-Velasco M; Rivera R; Carrascosa JM; de la Cueva-Dovao P; Armesto-Santos S; Ruíz-Villaverde R; Velasco-Pastor M; Magdaleno-Tapial J; Yanguas-Bayona JI; Ribera-Pibernat M; Salgado-Boquete L; Herranz-Pinto P; Romero-Mate A; Martínez-Lorenzo E; López-Estebaranz JL; Ballescá-López F; Botella-Estrada R
Australas J Dermatol; 2023 Nov; 64(4):e317-e326. PubMed ID: 37435962
[TBL] [Abstract][Full Text] [Related]
8. Management of moderate to severe psoriasis with brodalumab-Real-world evidence from the LIBERO study.
von Kiedrowski R; Hinz T; Mauer G; Schwinn A; Timmel A; Hutt HJ; Augustin M
J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38572773
[TBL] [Abstract][Full Text] [Related]
9. Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.
Mastorino L; Dapavo P; Burzi L; Rosset F; Giunipero di Corteranzo I; Leo F; Verrone A; Stroppiana E; Ortoncelli M; Ribero S; Quaglino P
Int J Dermatol; 2024 Jan; ():. PubMed ID: 38284277
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases.
Armstrong A; Fried R; Koo J; Gottlieb A; Jackson A
J Drugs Dermatol; 2023 Oct; 22(10):994-1000. PubMed ID: 37801526
[TBL] [Abstract][Full Text] [Related]
11. Individual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update.
Issa NT; Kircik L
J Drugs Dermatol; 2023 Oct; 22(10):SF378632s5-SF378632s15. PubMed ID: 37801535
[TBL] [Abstract][Full Text] [Related]
12. Brodalumab: 5-Year US Pharmacovigilance Report.
Lebwohl MG; Koo JY; Armstrong AW; Strober BE; Martin GM; Rawnsley NN; Goehring EL; Jacobson AA
Dermatol Ther (Heidelb); 2024 May; 14(5):1349-1357. PubMed ID: 38724839
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort.
Caldarola G; Galluzzo M; Bernardini N; Botti E; De Luca E; De Simone C; Mariani M; Moretta G; Pallotta S; Campione E; Peris K
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810071
[TBL] [Abstract][Full Text] [Related]
14. Brodalumab: 4-Year US Pharmacovigilance Report.
Lebwohl M; Koo J; Leonardi C; Armstrong A; Rawnsley N; Goehring E; Jacobson A
J Drugs Dermatol; 2023 Apr; 22(4):419-422. PubMed ID: 37026879
[TBL] [Abstract][Full Text] [Related]
15. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Wu S; Xu Y; Yang L; Guo L; Jiang X
Front Immunol; 2023; 14():1294416. PubMed ID: 38106423
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas.
Cacciapuoti S; Potestio L; Guerrasio G; Fabbrocini G; Scalvenzi M; Ruggiero A; Caiazzo G; Megna M
Clin Cosmet Investig Dermatol; 2023; 16():2637-2644. PubMed ID: 37780688
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic T-Cell Responses in Immune-Mediated Glomerulonephritis.
Linke A; Tiegs G; Neumann K
Cells; 2022 May; 11(10):. PubMed ID: 35626662
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
